Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Presents Positive Phase I Data on Cholesterol Drug Candidate


Alnylam Pharmaceuticals last week released data from a phase I study of its siRNA-based hypercholesterolemia drug ALN-PCS, reporting that a single dose of the agent could significantly and durably lower both its target and low-density lipoprotein cholesterol levels.

In the study, 32 healthy volunteers with elevated LDL were enrolled into six sequential dose cohorts, ranging from 0.015 mg/kg to 0.4 mg/kg. Patients were randomized to receive either drug or placebo.

According to Alnylam, drug treatment led to “rapid, dose-dependent, and durable reductions in LDL-C of up to 50 percent relative to baseline and placebo, with a statistically significant mean reduction of 41 percent at the 0.4 mg/kg dose level.”

Additionally, treatment triggered an up to 84 percent reduction in plasma levels of the drug's target, proprotein convertase subtilisn/kexin type 9, with a mean reduction of 68 percent in the highest dose group. A dose-dependent decrease in the proportion of subjects achieving target levels of LDL-C was also observed.

“The effects of a single dose of ALN-PCS support a once-monthly dose administration regimen for future studies,” Alnylam said.

No serious adverse events related to ALN-PCS were observed, and there was no significant change compared to baseline in levels of high-density lipoprotein.

ALN-PCS comprises siRNAs that are delivered using the so-called MC3 lipid nanoparticle technology, to which both Alnylam and partner Tekmira Pharmaceuticals have laid claim (GSN 3/17/2011).

Earlier this year, after releasing positive preliminary phase I data, Alnylam said that it would not advance ALN-PCS into later-stage clinical testing without a partner (GSN 1/12/2012).

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.